Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town

D. D. Barth, P. Naicker, K. Engel, B. Muhamed, W. Basera, B. M. Mayosi, J. B. Dale, M. E. Engel

Research output: Contribution to journalArticle

Abstract

Group A streptococcus (GAS) is responsible for a wide range of noninvasive group A streptococcal (non-iGAS) and invasive group A streptococcal (iGAS) infections. Information about the emm type variants of the M protein causing GAS disease is important to assess potential vaccine coverage of a 30-valent vaccine under development, particularly with respect to how they compare and contrast with non-iGAS isolates, especially in regions with a high burden of GAS. We conducted a prospective passive surveillance study of samples from patients attending public health facilities in Cape Town, South Africa. We documented demographic data and clinical presentation. emm typing was conducted using CDC protocols. GAS was commonly isolated from pus swabs, blood, deep tissue, and aspirates. Clinical presentations included wound infections (20%), bacteremia (15%), abscesses (9%), and septic arthritis (8%). Forty-six different emm types were identified, including M76 (16%), M81 (10%), M80 (6%), M43 (6%), and M183 (6%), and the emm types were almost evenly distributed between non-iGAS and iGAS isolates. There was a statistically significant association with M80 in patients presenting with noninvasive abscesses. Compared to the 30-valent vaccine under development, the levels of potential vaccine coverage for non-iGAS and iGAS infection were 60% and 58%, respectively, notably lower than the coverage in developed countries; five of the most prevalent emm types, M76, M81, M80, M43, and M183, were not included. The emm types from GAS isolated from patients with invasive disease did not differ significantly from those from noninvasive disease cases. There is low coverage of the multivalent M protein vaccine in our setting, emphasizing the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.IMPORTANCE The development of a vaccine for group A streptococcus (GAS) is of paramount importance given that GAS infections cause more than 500,000 deaths annually across the world. This prospective passive surveillance laboratory study evaluated the potential coverage of the M protein-based vaccine currently under development. While a number of GAS strains isolated from this sub-Sahara African study were included in the current vaccine formulation, we nevertheless report that potential vaccine coverage for GAS infection in our setting was approximately 60%, with four of the most prevalent strains not included. This research emphasizes the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.

Original languageEnglish
JournalMsphere
Volume4
Issue number5
DOIs
Publication statusPublished - 30 Oct 2019

Fingerprint

Streptococcal Infections
Molecular Epidemiology
Streptococcus
Vaccines
Abscess
Public Facilities
Northern Africa
Infectious Arthritis
Proteins
Suppuration
Health Facilities
Wound Infection
Centers for Disease Control and Prevention (U.S.)
Bacteremia
South Africa
Infection
Developed Countries
Public Health
Demography

Cite this

Barth, D. D. ; Naicker, P. ; Engel, K. ; Muhamed, B. ; Basera, W. ; Mayosi, B. M. ; Dale, J. B. ; Engel, M. E. / Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town. In: Msphere. 2019 ; Vol. 4, No. 5.
@article{6220579cab904703adf97fea761b1453,
title = "Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town",
abstract = "Group A streptococcus (GAS) is responsible for a wide range of noninvasive group A streptococcal (non-iGAS) and invasive group A streptococcal (iGAS) infections. Information about the emm type variants of the M protein causing GAS disease is important to assess potential vaccine coverage of a 30-valent vaccine under development, particularly with respect to how they compare and contrast with non-iGAS isolates, especially in regions with a high burden of GAS. We conducted a prospective passive surveillance study of samples from patients attending public health facilities in Cape Town, South Africa. We documented demographic data and clinical presentation. emm typing was conducted using CDC protocols. GAS was commonly isolated from pus swabs, blood, deep tissue, and aspirates. Clinical presentations included wound infections (20{\%}), bacteremia (15{\%}), abscesses (9{\%}), and septic arthritis (8{\%}). Forty-six different emm types were identified, including M76 (16{\%}), M81 (10{\%}), M80 (6{\%}), M43 (6{\%}), and M183 (6{\%}), and the emm types were almost evenly distributed between non-iGAS and iGAS isolates. There was a statistically significant association with M80 in patients presenting with noninvasive abscesses. Compared to the 30-valent vaccine under development, the levels of potential vaccine coverage for non-iGAS and iGAS infection were 60{\%} and 58{\%}, respectively, notably lower than the coverage in developed countries; five of the most prevalent emm types, M76, M81, M80, M43, and M183, were not included. The emm types from GAS isolated from patients with invasive disease did not differ significantly from those from noninvasive disease cases. There is low coverage of the multivalent M protein vaccine in our setting, emphasizing the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.IMPORTANCE The development of a vaccine for group A streptococcus (GAS) is of paramount importance given that GAS infections cause more than 500,000 deaths annually across the world. This prospective passive surveillance laboratory study evaluated the potential coverage of the M protein-based vaccine currently under development. While a number of GAS strains isolated from this sub-Sahara African study were included in the current vaccine formulation, we nevertheless report that potential vaccine coverage for GAS infection in our setting was approximately 60{\%}, with four of the most prevalent strains not included. This research emphasizes the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.",
keywords = "group A streptococcus, invasive GAS, molecular epidemiology, sub-Saharan Africa, vaccines",
author = "Barth, {D. D.} and P. Naicker and K. Engel and B. Muhamed and W. Basera and Mayosi, {B. M.} and Dale, {J. B.} and Engel, {M. E.}",
year = "2019",
month = "10",
day = "30",
doi = "10.1128/mSphere.00421-19",
language = "English",
volume = "4",
journal = "Msphere",
issn = "1535-9778",
publisher = "American Society for Microbiology",
number = "5",

}

Barth, DD, Naicker, P, Engel, K, Muhamed, B, Basera, W, Mayosi, BM, Dale, JB & Engel, ME 2019, 'Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town' Msphere, vol. 4, no. 5. https://doi.org/10.1128/mSphere.00421-19

Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town. / Barth, D. D.; Naicker, P.; Engel, K.; Muhamed, B.; Basera, W.; Mayosi, B. M.; Dale, J. B.; Engel, M. E.

In: Msphere, Vol. 4, No. 5, 30.10.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town

AU - Barth, D. D.

AU - Naicker, P.

AU - Engel, K.

AU - Muhamed, B.

AU - Basera, W.

AU - Mayosi, B. M.

AU - Dale, J. B.

AU - Engel, M. E.

PY - 2019/10/30

Y1 - 2019/10/30

N2 - Group A streptococcus (GAS) is responsible for a wide range of noninvasive group A streptococcal (non-iGAS) and invasive group A streptococcal (iGAS) infections. Information about the emm type variants of the M protein causing GAS disease is important to assess potential vaccine coverage of a 30-valent vaccine under development, particularly with respect to how they compare and contrast with non-iGAS isolates, especially in regions with a high burden of GAS. We conducted a prospective passive surveillance study of samples from patients attending public health facilities in Cape Town, South Africa. We documented demographic data and clinical presentation. emm typing was conducted using CDC protocols. GAS was commonly isolated from pus swabs, blood, deep tissue, and aspirates. Clinical presentations included wound infections (20%), bacteremia (15%), abscesses (9%), and septic arthritis (8%). Forty-six different emm types were identified, including M76 (16%), M81 (10%), M80 (6%), M43 (6%), and M183 (6%), and the emm types were almost evenly distributed between non-iGAS and iGAS isolates. There was a statistically significant association with M80 in patients presenting with noninvasive abscesses. Compared to the 30-valent vaccine under development, the levels of potential vaccine coverage for non-iGAS and iGAS infection were 60% and 58%, respectively, notably lower than the coverage in developed countries; five of the most prevalent emm types, M76, M81, M80, M43, and M183, were not included. The emm types from GAS isolated from patients with invasive disease did not differ significantly from those from noninvasive disease cases. There is low coverage of the multivalent M protein vaccine in our setting, emphasizing the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.IMPORTANCE The development of a vaccine for group A streptococcus (GAS) is of paramount importance given that GAS infections cause more than 500,000 deaths annually across the world. This prospective passive surveillance laboratory study evaluated the potential coverage of the M protein-based vaccine currently under development. While a number of GAS strains isolated from this sub-Sahara African study were included in the current vaccine formulation, we nevertheless report that potential vaccine coverage for GAS infection in our setting was approximately 60%, with four of the most prevalent strains not included. This research emphasizes the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.

AB - Group A streptococcus (GAS) is responsible for a wide range of noninvasive group A streptococcal (non-iGAS) and invasive group A streptococcal (iGAS) infections. Information about the emm type variants of the M protein causing GAS disease is important to assess potential vaccine coverage of a 30-valent vaccine under development, particularly with respect to how they compare and contrast with non-iGAS isolates, especially in regions with a high burden of GAS. We conducted a prospective passive surveillance study of samples from patients attending public health facilities in Cape Town, South Africa. We documented demographic data and clinical presentation. emm typing was conducted using CDC protocols. GAS was commonly isolated from pus swabs, blood, deep tissue, and aspirates. Clinical presentations included wound infections (20%), bacteremia (15%), abscesses (9%), and septic arthritis (8%). Forty-six different emm types were identified, including M76 (16%), M81 (10%), M80 (6%), M43 (6%), and M183 (6%), and the emm types were almost evenly distributed between non-iGAS and iGAS isolates. There was a statistically significant association with M80 in patients presenting with noninvasive abscesses. Compared to the 30-valent vaccine under development, the levels of potential vaccine coverage for non-iGAS and iGAS infection were 60% and 58%, respectively, notably lower than the coverage in developed countries; five of the most prevalent emm types, M76, M81, M80, M43, and M183, were not included. The emm types from GAS isolated from patients with invasive disease did not differ significantly from those from noninvasive disease cases. There is low coverage of the multivalent M protein vaccine in our setting, emphasizing the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.IMPORTANCE The development of a vaccine for group A streptococcus (GAS) is of paramount importance given that GAS infections cause more than 500,000 deaths annually across the world. This prospective passive surveillance laboratory study evaluated the potential coverage of the M protein-based vaccine currently under development. While a number of GAS strains isolated from this sub-Sahara African study were included in the current vaccine formulation, we nevertheless report that potential vaccine coverage for GAS infection in our setting was approximately 60%, with four of the most prevalent strains not included. This research emphasizes the need to reformulate the vaccine to improve coverage in areas where the burden of disease is high.

KW - group A streptococcus

KW - invasive GAS

KW - molecular epidemiology

KW - sub-Saharan Africa

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85074368348&partnerID=8YFLogxK

U2 - 10.1128/mSphere.00421-19

DO - 10.1128/mSphere.00421-19

M3 - Article

VL - 4

JO - Msphere

JF - Msphere

SN - 1535-9778

IS - 5

ER -